Idorsia Ltd
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03688555
- Locations
- 🇧🇪
University Hospital Ghent, Gent, Belgium
🇩🇪Charité Research Organisation GmbH, Berlin, Germany
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 804
- Registration Number
- NCT03679884
- Locations
- 🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇺🇸Preferred Research Partners, Inc, Little Rock, Arkansas, United States
🇺🇸Core Healthcare Group, Cerritos, California, United States
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03657446
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT03657355
- Locations
- 🇨🇦
Altasciences Company Inc., Montreal, Canada
🇺🇸Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park, Kansas, United States
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03646864
- Locations
- 🇩🇪
framol-med GmbH, Lungenpraxis, Rheinau, Germany
🇩🇪Advanced Sleep Research, Berlin, Germany
🇩🇪ZMS, Warendorf, Germany
A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03609775
- Locations
- 🇳🇱
Centre For Human Drug Research, Leiden, Netherlands
A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03596294
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03593278
- Locations
- 🇩🇪
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany
🇩🇪Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany
🇩🇪Universitäts-Herzzentrum Freiburg, Freiburg, Germany
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03586570
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
- Conditions
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 409
- Registration Number
- NCT03585270
- Locations
- 🇺🇸
University of Illinois - Department of Neurosurgery, Chicago, Illinois, United States
🇺🇸University Hospitals Case Medical Center - Department of Neurosurgery, Cleveland, Ohio, United States
🇭🇺Debreceni Egyetem, Idegsebészet, Debrecen, Hungary